Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small...

Area of Science:

• Oncology
• Translational Research
• Clinical Informatics

Background:

• Guidelines recommend predictive biomarker testing for non-small cell lung cancer (NSCLC).
• Widespread adoption of biomarker testing and targeted therapy in clinical practice remains suboptimal.
• Understanding patterns in testing and treatment is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the impact of clinical pathways on biomarker testing rates.
• To assess the subsequent selection of first-line targeted therapies in metastatic NSCLC patients.
• To compare testing and treatment patterns between community and academic cancer programs.

Main Methods:

• Analysis of patient data from 7 cancer programs utilizing clinical pathways software.
• Data collection on predictive biomarker testing and first-line treatment selection.
• Stratification of findings based on provider type (community vs. academic).

Main Results:

• High rates of biomarker testing were observed among providers using clinical pathways.
• Appropriate selection of first-line targeted therapies was noted in conjunction with pathway use.
• Clinical pathways facilitated adherence to testing recommendations.

Conclusions:

• Clinical pathways can effectively promote essential biomarker testing in NSCLC.
• Pathway implementation supports appropriate targeted therapy selection.
• These tools can assist oncology practices in optimizing patient care pathways.